KYORIN Taps Lunatus to Launch Antibacterial Drug Lasvic Across Middle East

KYORIN Pharmaceutical Co.,Ltd. ( (JP:4569) ) has provided an announcement.

KYORIN Pharmaceutical has signed an exclusive distribution agreement with Dubai-based Lunatus Marketing & Consulting to supply its oral fluoroquinolone antibacterial drug Lasvic (lascufloxacin hydrochloride) for respiratory and ENT infections across nine Middle Eastern countries, including Saudi Arabia, the UAE and Qatar. Under the deal, KYORIN will act as Marketing Authorization Holder and provide the product to Lunatus, which will leverage its regional regulatory, marketing and distribution network to build Lasvic’s presence, aligning with KYORIN’s strategy to maximize the value of its proprietary products through out-licensing; while the immediate impact on earnings for the fiscal year ending March 2026 is expected to be negligible, the partnership strengthens KYORIN’s long-term positioning in the Middle East anti-infective market and supports broader Japan–Middle East collaboration in healthcare.

The most recent analyst rating on (JP:4569) stock is a Hold with a Yen1653.00 price target. To see the full list of analyst forecasts on KYORIN Pharmaceutical Co.,Ltd. stock, see the JP:4569 Stock Forecast page.

More about KYORIN Pharmaceutical Co.,Ltd.

KYORIN Pharmaceutical Co., Ltd. is a Japanese pharmaceutical company focused on developing proprietary prescription drugs, including anti-infective agents for respiratory and ear, nose and throat (ENT) diseases. As part of its medium-term business plan “Vision 110 – Stage 1 –”, the company is emphasizing out-licensing and international partnerships to expand the global reach of its products and enhance its presence in key overseas markets.

Average Trading Volume: 132,467

Technical Sentiment Signal: Buy

Current Market Cap: Yen80.91B

See more insights into 4569 stock on TipRanks’ Stock Analysis page.